Profile of INMED PHARMACEUTICALS INC(NASDAQ:INM) stock

INMED PHARMACEUTICALS INC2.2

NASDAQ:INM (2/3/2023, 3:08:36 PM)+0.12 (+5.77%)

After market: 2.12 -0.08 (-3.64%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Pharmaceuticals

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	09-23 2022-09-23/dmh	Earnings (Next)	02-13 2023-02-13
Ins Owners	4.66%	Inst Owners	0.01%
Market Cap	17.71M	Shares	8.05M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	45
IPO	06-21 2001-06-21

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The company is developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with unmet medical needs (Product Candidates). The Company’s segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceuticals products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides both neuroprotection and reduces intraocular pressure in the eye.